Evidence map›Paper›PMID 41861111›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Ferroptosis Induction by Fenbendazole Combined With Photothermal Therapy Triggers Dual-Immunotherapy Against Bladder Cancer.

Xiaojian Xu, Rui Liang, Anguo Zhao, Jun Zhang, Rongkang Li, Yang Liu, Dashi Deng, Qi Zhuang, Lisha Liu, Lei Peng and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaojian XuDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Rui LiangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Anguo ZhaoDepartment of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, China.
Jun ZhangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0001-9416-3713
Rongkang LiDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Yang LiuDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Dashi DengDepartment of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Qi ZhuangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Lisha LiuDepartment of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Lei PengDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Miao LiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID https://orcid.org/0000-0003-4295-370X
Xuedong WeiDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yuhua HuangDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Shaohua ZhangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Liang ChengInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon Based Functional Materials & Devices, Soochow University, Shenzhen, China.ORCID https://orcid.org/0000-0001-5324-9094
Jianquan HouDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

National Natural Science Foundation of China 82572292Sanming Project of Medicine in Shenzhen SZSM202211009Shenzhen Engineering Research Center XMHT20220104016Soochow Youth Science and Technology Project of "Science and Education Prosper Health KJXW2023002
6 · The paper itself

Abstract

Ferroptosis, a newly recognized form of regulated cell death, has emerged as a promising strategy in cancer therapy. Given the high incidence and recurrence rates of bladder cancer, exploring novel therapeutic approaches is critically important. In this study, we developed a novel intravesical nanoplatform, FBZ@BSA@PDA, that integrates ferroptosis-related oxidative injury immunogenic cell death (ICD) activation, and photothermal therapy (PTT) to achieve synergistic treatment of bladder cancer. The hydrophobic drug fenbendazole (FBZ) was efficiently encapsulated via thermally induced unfolding of bovine serum albumin (BSA), and polydopamine (PDA) was formed by in situ polymerization of dopamine to enhance tissue adhesion and photothermal responsiveness. Following transurethral intravesical administration, the platform enabled sustained drug release and localized PTT. Mechanistically, it induced lipid peroxidation (LPO), GSH depletion, and mitochondrial dysfunction, which suggest that ferroptosis may contribute to tumor cell death. This was accompanied by key ICD markers, including calreticulin (CRT) exposure, high mobility group box 1 (HMGB1) release, and adenosine triphosphate (ATP) secretion, which effectively promoted dendritic cell (DC) maturation and T-cell activation. FBZ@BSA@PDA demonstrated strong anti-tumor efficacy and favorable biosafety in an orthotopic mouse model of bladder cancer. This strategy offers a promising localized immune-potentiated therapeutic approach for clinical bladder cancer treatment.

Indexed as

FerroptosisImmunotherapyPhotothermal TherapyUrinary Bladder NeoplasmsAnimalsCell Line, TumorFemaleHumansIndolesMicePolymersIndolespolydopaminePolymersbladder cancerferroptosisflubendazolephotothermal therapypolydopamine

Identifiers

PMID41861111
PMCPMC13587987

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.